Zydus Lifesciences informs about press release
Date: 21-10-2026Zydus Lifesciences has informed that it enclosed a copy of press release dated October 21, 2026, titled ‘Zydus receives USFDA approval for Estradiol and Levonorgestrel Transdermal System, eligible for 180-day CGT exclusivity’. The contents of the press release give full details.
The above information is a part of company’s filings submitted to BSE.